Abstract 1630P
Background
Patients with cancer were excluded from initial clinical trials assessing anti-SARS-CoV2 vaccines. The aim of this study is to evaluate the safety and effectivity of anti-SARS-CoV2 vaccination in patients with lung cancer.
Methods
This observational non-interventionist study included patients diagnosed with lung cancer of any histology and tumor stage who had received at least one dose of anti-SARS-CoV2 vaccine approved by EMA and who signed the informed consent. The study was promoted by the Spanish Lung Cancer Group (GECP).
Results
794 patients from 27 centers were included in the study between January and October 2021. Main patients’ characteristics are shown in the table. Most patients (71.8%) were receiving active treatment when received the vaccination: chemotherapy (45.8%), immunotherapy (38.2%), radiotherapy (13.4%) and targeted therapy (14.5%). Only 9.7% of patients have had COVID-19 before vaccination. Most patients received mRNA vaccines at any vaccination round: 1st, 86.4%; 2nd, 87%; 3rd, 73.2% and most received the second (98.2%) and third booster dose (74.7%). Most vaccine-related adverse events were grade 1 (79.6%) or grade 2 (17%) and only 7 patients experienced grade 3 and 1 patient grade 4 toxicity. There were 58 cases of COVID-19 (7.3%) but most were asymptomatic or paucisymptomatic (62.1%). Only 10 patients (1.3%) were admitted at the hospital, but none require intensive unit support. During study follow-up, 9 patients died due to cancer or to other causes, no COVID-19-related deaths after receiving the vaccination were recorded. Table: 1630P
| Patients’ characteristics | |
| Age, median (range) | 66 (33.91) |
| Gender, n (%) Male Female | 511 (64.4%) 283 (35.6%) |
| Smoking status, n (%) Former smoker Current smoker Never smoker Unknown | 420 (52.9%) 257 (32.4%) 115 (14.5%) 2 (0.3%) |
| ECOG Performance Status, n (%) 0 1 2 | 278 (35%) 483 (60.8%) 32 (4.2%) |
| Histology, n (%) Non-small cell lung cancer Small cell lung cancer Other | 704 (88.7%) 76 (9.6%) 14 (1.7%) |
| Tumor stage, n (%) I-II III IV Unknown | 109 (13.7%) 161 (20.3%) 449 (56.5%) 75 (9.4%) |
Conclusions
Anti-SARS-CoV-2 vaccines are safe in patients with lung cancer and most vaccine-related adverse events were mild or moderate. The rate of COVID-19 infection is low in this cohort of vaccinated patients with lung cancer and most COVID-19 cases were mild and managed without hospitalization.
Clinical trial identification
NCT05009030.
Editorial acknowledgement
Legal entity responsible for the study
Fundacion GECP (Spanish Lung Cancer Group).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.